context|end|flags|hp_id|index|line|names|negated|pat_id|relevant|score|section|start
|140.0|{'associated'}|HP:0002037|0.0|DOI: https://www.wjgnet.com/1007-9327/full/v26/i15/1841.htm<br><br><br>Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report<br>Advanced Search<br>BPG is committed to discovery and dissemination of knowledge<br>This Article<br>AddThis Sharing ButtonsShare to FacebookFacebookShare to TwitterTwitterShare to E-mailEmailShare to Meer... AddThis<br><h5><br>Academic Content and Language Evaluation of This Article<br><h5><br>CrossCheck and Google Search of This Article<br><h5><br>Academic Rules and Norms of This Article<br><h5><br>Citation of this article<br>Fagbemi A, Newman WG, Tangye SG, Hughes SM, Cheesman E, Arkwright PD.|['Inflammation of the large intestine']|0.0|None|0.0|1|Unassigned|70.0
|30.0|{'associated'}|HP:0002037|1.0|Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report.|['Inflammation of the large intestine']|0.0|None|0.0|1|Unassigned|15.0
|58.0|set()|HP:0012393|2.0|2020: 26(15): 1841-1846<br><h5><br>Corresponding Author of This Article<br>Peter D Arkwright, MD, PhD, Senior Lecturer, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Oxford Road, Manchester M139WL, United Kingdom.|['Allergy']|0.0|None|0.0|1|Unassigned|29.0
(c)The Author(s) 2020.. Published by Baishideng Publishing Group Inc. All rights reserved.<br>World J Gastroenterol.. Apr 21, 2020: 26(15): 1841-1846<br>. Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1841<br>Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report<br>Andrew Fagbemi, William G Newman, Stuart G Tangye, Stephen M Hughes, Edmund Cheesman, Peter D Arkwright<br>Andrew Fagbemi, Department of Paediatric Gastroenterology, Royal Manchester Children's Hospital, Manchester M199WL, United KingdomWilliam G Newman, Department of Medical Genetics, Manchester University NHS Foundation Trust, Manchester M139WL, United KingdomWilliam G Newman, Evolution and Genomic Sciences, University of Manchester, Manchester M139WL, United KingdomStuart G Tangye, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, AustraliaStuart G Tangye, St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, NSW 2010, AustraliaStephen M Hughes, Peter D Arkwright, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester M139WL, United KingdomEdmund Cheesman, Department of Paediatric Histopathology, St Mary's Hospital, Manchester M139WL, United KingdomPeter D Arkwright, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester M139WL, United Kingdom<br>ORCID number: Andrew Fagbemi (0000-0002-3967-3777): William G Newman (0000-0002-6382-4678): Stuart G Tangye (0000-0002-5360-5180): Stephen M Hughes (0000-0001-9985-3908): Edmund Cheesman (0000-0001-5546-6965): Peter D Arkwright (0000-0002-7411-5375).<br>Author contributions:  Arkwright PD and Newman WG led the study concept and design: all authors were involved in acquisition of data: Arkwright PD, Newman WG, Cheesman E and Tangye SG analysed and interpreted the data: Arkwright PD drafted the manuscript and all authors critically reviewed the manuscript.<br>. Informed consent statement:  Informed consent was obtained from the child's parents for the publication of the report.. Conflict-of-interest statement:  The authors have declared no conflicts of interest.|220.0|{'study', 'associated'}|HP:0002037|17.0|Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1841<br>Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report<br>Andrew Fagbemi, William G Newman, Stuart G Tangye, Stephen M Hughes, Edmund Cheesman, Peter D Arkwright<br>Andrew Fagbemi, Department of Paediatric Gastroenterology, Royal Manchester Children's Hospital, Manchester M199WL, United KingdomWilliam G Newman, Department of Medical Genetics, Manchester University NHS Foundation Trust, Manchester M139WL, United KingdomWilliam G Newman, Evolution and Genomic Sciences, University of Manchester, Manchester M139WL, United KingdomStuart G Tangye, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, AustraliaStuart G Tangye, St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, NSW 2010, AustraliaStephen M Hughes, Peter D Arkwright, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester M139WL, United KingdomEdmund Cheesman, Department of Paediatric Histopathology, St Mary's Hospital, Manchester M139WL, United KingdomPeter D Arkwright, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester M139WL, United Kingdom<br>ORCID number: Andrew Fagbemi (0000-0002-3967-3777): William G Newman (0000-0002-6382-4678): Stuart G Tangye (0000-0002-5360-5180): Stephen M Hughes (0000-0001-9985-3908): Edmund Cheesman (0000-0001-5546-6965): Peter D Arkwright (0000-0002-7411-5375).<br>Author contributions:  Arkwright PD and Newman WG led the study concept and design: all authors were involved in acquisition of data: Arkwright PD, Newman WG, Cheesman E and Tangye SG analysed and interpreted the data: Arkwright PD drafted the manuscript and all authors critically reviewed the manuscript.<br>|['Inflammation of the large intestine']|0.0|None|0.0|1|Unassigned|110.0
(c)The Author(s) 2020.. Published by Baishideng Publishing Group Inc. All rights reserved.<br>World J Gastroenterol.. Apr 21, 2020: 26(15): 1841-1846<br>. Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1841<br>Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report<br>Andrew Fagbemi, William G Newman, Stuart G Tangye, Stephen M Hughes, Edmund Cheesman, Peter D Arkwright<br>Andrew Fagbemi, Department of Paediatric Gastroenterology, Royal Manchester Children's Hospital, Manchester M199WL, United KingdomWilliam G Newman, Department of Medical Genetics, Manchester University NHS Foundation Trust, Manchester M139WL, United KingdomWilliam G Newman, Evolution and Genomic Sciences, University of Manchester, Manchester M139WL, United KingdomStuart G Tangye, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, AustraliaStuart G Tangye, St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, NSW 2010, AustraliaStephen M Hughes, Peter D Arkwright, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester M139WL, United KingdomEdmund Cheesman, Department of Paediatric Histopathology, St Mary's Hospital, Manchester M139WL, United KingdomPeter D Arkwright, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester M139WL, United Kingdom<br>ORCID number: Andrew Fagbemi (0000-0002-3967-3777): William G Newman (0000-0002-6382-4678): Stuart G Tangye (0000-0002-5360-5180): Stephen M Hughes (0000-0001-9985-3908): Edmund Cheesman (0000-0001-5546-6965): Peter D Arkwright (0000-0002-7411-5375).<br>Author contributions:  Arkwright PD and Newman WG led the study concept and design: all authors were involved in acquisition of data: Arkwright PD, Newman WG, Cheesman E and Tangye SG analysed and interpreted the data: Arkwright PD drafted the manuscript and all authors critically reviewed the manuscript.<br>. Informed consent statement:  Informed consent was obtained from the child's parents for the publication of the report.. Conflict-of-interest statement:  The authors have declared no conflicts of interest.|330.0|{'study', 'associated'}|HP:0012393|17.0|Published online Apr 21, 2020. doi: 10.3748/wjg.v26.i15.1841<br>Refractory very early-onset inflammatory bowel disease associated with cytosolic isoleucyl-tRNA synthetase deficiency: A case report<br>Andrew Fagbemi, William G Newman, Stuart G Tangye, Stephen M Hughes, Edmund Cheesman, Peter D Arkwright<br>Andrew Fagbemi, Department of Paediatric Gastroenterology, Royal Manchester Children's Hospital, Manchester M199WL, United KingdomWilliam G Newman, Department of Medical Genetics, Manchester University NHS Foundation Trust, Manchester M139WL, United KingdomWilliam G Newman, Evolution and Genomic Sciences, University of Manchester, Manchester M139WL, United KingdomStuart G Tangye, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, AustraliaStuart G Tangye, St Vincent's Clinical School, Faculty of Medicine, UNSW Australia, Sydney, NSW 2010, AustraliaStephen M Hughes, Peter D Arkwright, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Manchester M139WL, United KingdomEdmund Cheesman, Department of Paediatric Histopathology, St Mary's Hospital, Manchester M139WL, United KingdomPeter D Arkwright, Lydia Becker Institute of Immunology and Inflammation, University of Manchester, Manchester M139WL, United Kingdom<br>ORCID number: Andrew Fagbemi (0000-0002-3967-3777): William G Newman (0000-0002-6382-4678): Stuart G Tangye (0000-0002-5360-5180): Stephen M Hughes (0000-0001-9985-3908): Edmund Cheesman (0000-0001-5546-6965): Peter D Arkwright (0000-0002-7411-5375).<br>Author contributions:  Arkwright PD and Newman WG led the study concept and design: all authors were involved in acquisition of data: Arkwright PD, Newman WG, Cheesman E and Tangye SG analysed and interpreted the data: Arkwright PD drafted the manuscript and all authors critically reviewed the manuscript.<br>|['Allergy']|0.0|None|0.0|1|Unassigned|220.0
CARE Checklist (2016) statement:  The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).. Open-Access:  This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.. See: http://creativecommons.org/licenses/by-nc/4.0/Corresponding author:  Peter D Arkwright, MD, PhD, Senior Lecturer, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Oxford Road, Manchester M139WL, United Kingdom.. peter.arkwright@manchester.ac.uk<br>. Received: January 6, 2020Peer-review started:  January 6, 2020First decision:  January 19, 2020Revised: March 26, 2020Accepted: April 1, 2020Article in press:  April 1, 2020Published online: April 21, 2020<br><h5><br>|54.0|set()|HP:0012393|23.0|See: http://creativecommons.org/licenses/by-nc/4.0/Corresponding author:  Peter D Arkwright, MD, PhD, Senior Lecturer, Department of Paediatric Allergy and Immunology, Royal Manchester Children's Hospital, Oxford Road, Manchester M139WL, United Kingdom.|['Allergy']|0.0|None|0.0|1|Unassigned|27.0
Received: January 6, 2020Peer-review started:  January 6, 2020First decision:  January 19, 2020Revised: March 26, 2020Accepted: April 1, 2020Article in press:  April 1, 2020Published online: April 21, 2020<br><h5><br>. Abstract<br><h5>BACKGROUND</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are highly conserved enzymes involved in attaching amino acids to tRNA promoting protein synthesis.. Although deficiencies of ARSs localized to the mitochondria classically present with neuropathology, the clinical features of cytosolic ARS deficiencies are more variable.. They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease.<br>. <br>|44.0|set()|HP:0012838|28.0|Although deficiencies of ARSs localized to the mitochondria classically present with neuropathology, the clinical features of cytosolic ARS deficiencies are more variable.|['Localized']|0.0|None|0.0|1|BACKGROUND|22.0
Abstract<br><h5>BACKGROUND</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are highly conserved enzymes involved in attaching amino acids to tRNA promoting protein synthesis.. Although deficiencies of ARSs localized to the mitochondria classically present with neuropathology, the clinical features of cytosolic ARS deficiencies are more variable.. They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease.<br>. <br>. <h5>CASE SUMMARY</h5>|30.0|{'associated', 'previously', 'never'}|HP:0012115|29.0|They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease.<br>|['Hepatitis']|0.0|None|0.0|1|BACKGROUND|15.0
They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease.<br>. <br>. <h5>CASE SUMMARY</h5>. A nine-year-old Bangladeshi boy presented with neonatal liver failure and deranged clotting, transaminitis and cholestasis.. His parents were first cousins.. Two older brothers and a sister were well.|16.0|set()|HP:0001399|32.0|A nine-year-old Bangladeshi boy presented with neonatal liver failure and deranged clotting, transaminitis and cholestasis.|['Hepatic failure']|0.0|None|1.0|1|CASE SUMMARY|8.0
They have previously been associated with neonatal hepatitis, but never with early-onset inflammatory bowel disease.<br>. <br>. <h5>CASE SUMMARY</h5>. A nine-year-old Bangladeshi boy presented with neonatal liver failure and deranged clotting, transaminitis and cholestasis.. His parents were first cousins.. Two older brothers and a sister were well.|24.0|set()|HP:0001396|32.0|A nine-year-old Bangladeshi boy presented with neonatal liver failure and deranged clotting, transaminitis and cholestasis.|['Cholestasis']|0.0|None|1.0|1|CASE SUMMARY|16.0
The patient suffered from loose stools from early infancy which became more troublesome and persistent from five years old with ten bloody motions a day.. Repeated endoscopies showed persistent pancolitis, which was refractory to mesalazine, corticosteroids, azathioprine, sirolimus and anti-TNF (adalimumab) therapy, but has improved recently with subcutaneous methotrexate.. Whole Genome Sequencing revealed a novel pathogenic missense variant (c.290A &gt: G) in the cytosolic isoleucyl-tRNA synthetase gene, leading to an amino acid substitution (p. Asp97Gly).. Pathogenic variants in other genes associated with inflammatory bowel disease (IBD) () were excluded.. Cytokine assays demonstrated markedly elevated IL-2, IL-5, IL-13, IL-9 and IL-10 by the patient's CD4 T-cells, while IL-17A, IL-17F, IFNb were lower, and TNFa not significantly different when compared to healthy controls.<br>. <br>|28.0|{'associated'}|HP:0002037|38.0|Pathogenic variants in other genes associated with inflammatory bowel disease (IBD) () were excluded.|['Inflammation of the large intestine']|0.0|None|1.0|1|CASE SUMMARY|14.0
Cytokine assays demonstrated markedly elevated IL-2, IL-5, IL-13, IL-9 and IL-10 by the patient's CD4 T-cells, while IL-17A, IL-17F, IFNb were lower, and TNFa not significantly different when compared to healthy controls.<br>. <br>. <h5>CONCLUSION</h5>. This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.|70.0|{'report'}|HP:0012115|42.0|This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.|['Hepatitis']|0.0|None|1.0|1|CONCLUSION|35.0
Cytokine assays demonstrated markedly elevated IL-2, IL-5, IL-13, IL-9 and IL-10 by the patient's CD4 T-cells, while IL-17A, IL-17F, IFNb were lower, and TNFa not significantly different when compared to healthy controls.<br>. <br>. <h5>CONCLUSION</h5>. This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.|105.0|{'report'}|HP:0002037|42.0|This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.|['Inflammation of the large intestine']|0.0|None|1.0|1|CONCLUSION|70.0
<br>. <h5>CONCLUSION</h5>. This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|34.0|{'report', 'patients'}|HP:0002037|43.0|This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>|['Inflammation of the large intestine']|0.0|None|0.0|1|INTRODUCTION|17.0
<br>. <h5>CONCLUSION</h5>. This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|51.0|{'report', 'patients'}|HP:0012115|43.0|This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>|['Hepatitis']|0.0|None|0.0|1|INTRODUCTION|34.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|8.0|set()|HP:0012838|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Localized']|0.0|None|0.0|1|INTRODUCTION|4.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|12.0|set()|HP:0001941|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Acidosis']|0.0|None|0.0|1|INTRODUCTION|8.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|16.0|set()|HP:0003128|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Lactic acidosis']|0.0|None|0.0|1|INTRODUCTION|12.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|20.0|set()|HP:0004902|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Congenital lactic acidosis']|0.0|None|0.0|1|INTRODUCTION|16.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|24.0|set()|HP:0001298|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Encephalopathy']|0.0|None|0.0|1|INTRODUCTION|20.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|28.0|set()|HP:0001508|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Failure to thrive']|0.0|None|0.0|1|INTRODUCTION|24.0
This case report provides evidence that recessive mutations in cytosolic isoleucyl-tRNA synthetase are a novel monogenic cause of IBD, which should be considered, particularly in infants and children with a history of neonatal hepatitis and very early-onset IBD poorly responsive to treatment.<br>Key Words: Inflammatory bowel disease, Hepatitis, Gene, Cytosolic isoleucine tRNA synthase<br>Core tip: Consider cytosolic isoleucyl-tRNA synthetase in children presenting with neonatal hepatitis and refractory very early-onset inflammatory bowel disease.. This case report provides evidence for a novel monogenic cause of inflammatory bowel disease that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br><h5>INTRODUCTION</h5>. Aminoacyl tRNA synthetases/ligases (ARSs) are a group of 20 ubiquitously expressed, highly conserved enzymes involved in attaching each specific amino acid to a tRNA to promote protein synthesis.. ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.|32.0|set()|HP:0001263|45.0|ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.|['Global developmental delay']|0.0|None|0.0|1|INTRODUCTION|28.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|6.0|{'patients'}|HP:0001263|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Global developmental delay']|0.0|None|0.0|1|INTRODUCTION|3.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|9.0|{'patients'}|HP:0000365|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Hearing impairment']|0.0|None|0.0|1|INTRODUCTION|6.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|12.0|{'patients'}|HP:0000407|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Sensorineural hearing impairment']|0.0|None|0.0|1|INTRODUCTION|9.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|15.0|{'patients'}|HP:0008527|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Congenital sensorineural hearing impairment']|0.0|None|0.0|1|INTRODUCTION|12.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|18.0|{'patients'}|HP:0001252|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Muscular hypotonia']|0.0|None|0.0|1|INTRODUCTION|15.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|21.0|{'patients'}|HP:0001290|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Generalized hypotonia']|0.0|None|0.0|1|INTRODUCTION|18.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|24.0|{'patients'}|HP:0001319|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Neonatal hypotonia']|0.0|None|0.0|1|INTRODUCTION|21.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|27.0|{'patients'}|HP:0000819|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Diabetes mellitus']|0.0|None|0.0|1|INTRODUCTION|24.0
ARS deficiencies localized to the mitochondria have been known for 40 years and classically present with lactic acidosis, encephalopathy, failure to thrive and global developmental delay.. Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>|30.0|{'patients'}|HP:0001397|48.0|The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.|['Hepatic steatosis']|0.0|None|0.0|1|INTRODUCTION|27.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|12.0|set()|HP:0000252|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Microcephaly']|0.0|None|0.0|1|INTRODUCTION|6.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|18.0|set()|HP:0011451|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Congenital microcephaly']|0.0|None|0.0|1|INTRODUCTION|12.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|24.0|set()|HP:0001263|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Global developmental delay']|0.0|None|0.0|1|INTRODUCTION|18.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|30.0|set()|HP:0001396|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Cholestasis']|0.0|None|0.0|1|INTRODUCTION|24.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|36.0|set()|HP:0001290|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Generalized hypotonia']|0.0|None|0.0|1|INTRODUCTION|30.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|42.0|set()|HP:0001319|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Neonatal hypotonia']|0.0|None|0.0|1|INTRODUCTION|36.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|48.0|set()|HP:0001249|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Intellectual disability']|0.0|None|0.0|1|INTRODUCTION|42.0
Clinical features of cytosolic ARS deficiency are more variable.. In 2016, three unrelated individuals harboring compound homozygous variants in cytosolic isoleucyl-tRNA synthetase (IARS) [p.(Arg418)(Ile1174Asn), p.(Arg254)(Pro437Leu) and p.(Val370Gly)(Asn992Asp) (MIM: 600709)] were reported.. The patients suffered growth and developmental delay, sensorineural hearing loss, muscular hypotonia, diabetes mellitus, hepatic dysfunction with steatosis and fibrosis, and zinc deficiency.. A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.. Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>|54.0|set()|HP:0001510|49.0|A further individual with compound heterozygous for the missense substitutions p.(Arg739Cys)(Phe556Ser) with microcephaly, growth and developmental delay and neonatal cholestasis was described in 2017 and a seven year old boy compound heterozygous for p.(Gln671fs)(Thr69Ile) has also been reported with hepatopathy, hypotonia, intellectual disability and growth retardation.|['Growth delay']|0.0|None|0.0|1|INTRODUCTION|48.0
Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>. <h5>Chief complaints</h5>. A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.|10.0|set()|HP:0011968|53.0|A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>|['Feeding difficulties']|0.0|None|1.0|1|Chief complaints|5.0
Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>. <h5>Chief complaints</h5>. A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.|15.0|set()|HP:0001824|53.0|A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>|['Weight loss']|0.0|None|1.0|1|Chief complaints|10.0
Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>. <h5>Chief complaints</h5>. A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.|20.0|set()|HP:0001399|53.0|A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>|['Hepatic failure']|0.0|None|1.0|1|Chief complaints|15.0
Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>. <h5>Chief complaints</h5>. A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.|25.0|set()|HP:0002329|53.0|A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>|['Drowsiness']|0.0|None|1.0|1|Chief complaints|20.0
Here, we present a child with cytosolic IARS deficiency, whose main clinical feature was refractory inflammatory bowel disease (IBD), hitherto not previously described in other patients with IARS deficiency.<br>. <h5>CASE PRESENTATION</h5>. <h5>Chief complaints</h5>. A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.|30.0|set()|HP:0001396|53.0|A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>|['Cholestasis']|0.0|None|1.0|1|Chief complaints|25.0
A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.. His diarrhea has been much more troublesome since the age of five years old with ten bloody stools a day.<br>. <h5>History of past illness</h5>. The patient was free from other medical history.<br>|20.0|set()|HP:0002014|56.0|His diarrhea has been much more troublesome since the age of five years old with ten bloody stools a day.<br>|['Diarrhea']|0.0|None|1.0|1|History of present illness|10.0
A nine-year-old Bangladeshi boy born in the United Kingdom presented with poor feeding, weight loss, drowsiness due to neonatal liver failure with deranged clotting, transaminitis and cholestasis.<br>. <h5>History of present illness</h5>. The patient suffered from loose stools from early infancy and was commenced on an amino acid formula from the age of two months with initial improvement.. His diarrhea has been much more troublesome since the age of five years old with ten bloody stools a day.<br>. <h5>History of past illness</h5>. The patient was free from other medical history.<br>|30.0|set()|HP:0025085|56.0|His diarrhea has been much more troublesome since the age of five years old with ten bloody stools a day.<br>|['Bloody diarrhea']|0.0|None|1.0|1|History of present illness|20.0
Two older brothers and a sister were well.<br>. <h5>Physical examination</h5>. On examination, he was microcephalic, with normal weight, height and gross motor development.. He was clubbed with mild hepatomegaly.<br>. <h5>Laboratory examinations</h5>. Serum orosomucoid concentration was persistently raised [1736-2685 mg/L (normal range 300-1200 mg/L)], as was his ESR [28-140 mm/h (normal range 4-10 mm/h)].|6.0|set()|HP:0002240|64.0|He was clubbed with mild hepatomegaly.<br>|['Hepatomegaly']|0.0|None|1.0|1|Physical examination|3.0
Two older brothers and a sister were well.<br>. <h5>Physical examination</h5>. On examination, he was microcephalic, with normal weight, height and gross motor development.. He was clubbed with mild hepatomegaly.<br>. <h5>Laboratory examinations</h5>. Serum orosomucoid concentration was persistently raised [1736-2685 mg/L (normal range 300-1200 mg/L)], as was his ESR [28-140 mm/h (normal range 4-10 mm/h)].|9.0|set()|HP:0012825|64.0|He was clubbed with mild hepatomegaly.<br>|['Mild']|0.0|None|1.0|1|Physical examination|6.0
Fecal calprotectin is intermittently elevated (peak 393 mcg/g), although the latest level is normal at 50 mcg/g.. Plasma zinc concentration was normal at 17.2 mol/L (10-18 mol/L).<br>. <h5>Imaging examinations</h5>. Abdominal ultrasound showed no signs of hepatosplenomegaly, but the liver had diffusely increased echogenicity consistent with fatty change, possibly related to weight gain associated with chronic corticosteroid use.<br>. <h5>Further diagnostic work-up</h5>. Liver biopsy showed hydropic degeneration of hepatocytes (Figure 1A).|18.0|{'associated', 'signs', 'no'}|HP:0001397|72.0|Abdominal ultrasound showed no signs of hepatosplenomegaly, but the liver had diffusely increased echogenicity consistent with fatty change, possibly related to weight gain associated with chronic corticosteroid use.<br>|['Hepatic steatosis']|0.0|None|1.0|1|Imaging examinations|9.0
Fecal calprotectin is intermittently elevated (peak 393 mcg/g), although the latest level is normal at 50 mcg/g.. Plasma zinc concentration was normal at 17.2 mol/L (10-18 mol/L).<br>. <h5>Imaging examinations</h5>. Abdominal ultrasound showed no signs of hepatosplenomegaly, but the liver had diffusely increased echogenicity consistent with fatty change, possibly related to weight gain associated with chronic corticosteroid use.<br>. <h5>Further diagnostic work-up</h5>. Liver biopsy showed hydropic degeneration of hepatocytes (Figure 1A).|27.0|{'associated', 'signs', 'no'}|HP:0004324|72.0|Abdominal ultrasound showed no signs of hepatosplenomegaly, but the liver had diffusely increased echogenicity consistent with fatty change, possibly related to weight gain associated with chronic corticosteroid use.<br>|['Increased body weight']|0.0|None|1.0|1|Imaging examinations|18.0
Fecal calprotectin is intermittently elevated (peak 393 mcg/g), although the latest level is normal at 50 mcg/g.. Plasma zinc concentration was normal at 17.2 mol/L (10-18 mol/L).<br>. <h5>Imaging examinations</h5>. Abdominal ultrasound showed no signs of hepatosplenomegaly, but the liver had diffusely increased echogenicity consistent with fatty change, possibly related to weight gain associated with chronic corticosteroid use.<br>. <h5>Further diagnostic work-up</h5>. Liver biopsy showed hydropic degeneration of hepatocytes (Figure 1A).|36.0|{'associated', 'signs', 'no'}|HP:0011010|72.0|Abdominal ultrasound showed no signs of hepatosplenomegaly, but the liver had diffusely increased echogenicity consistent with fatty change, possibly related to weight gain associated with chronic corticosteroid use.<br>|['Chronic']|0.0|None|1.0|1|Imaging examinations|27.0
<h5>Further diagnostic work-up</h5>. Liver biopsy showed hydropic degeneration of hepatocytes (Figure 1A).. There was no evidence of mitochondrial DNA depletion and plasma lactate was normal.. Repeated endoscopy at 6, 7 and 8 years old showed persistent chronic inflammation in the cecum, and pancolitis with diffuse inflammation, superficial ulceration, distortion of the crypt architecture and crypt abscess formation, in a distribution similar to that found in ulcerative colitis (Figure 1B).. There were no inflammatory changes in the esophagus, stomach and duodenum, nor were there any granuloma to suggest Crohn's disease.<br>Figure 1 Histology and blood leukocyte cytokine profile of patient with cytosolic isoleucyl-tRNA synthetase deficiency.<br>A: Liver histology showing hydropic change, but no classic apoptosis of the hepatocytes: B: Pancolitis, with diffuse increase in inflammatory cells, cryptitis and crypt abscess formation.. High power insert: A few apoptotic epithelial cells seen, but within normal limits, c/cytokine profile: C: Cytokine secretion from peripheral blood leukocytes of patient with isoleucyl-tRNA synthetase deficiency compared with healthy donor.|30.0|set()|HP:0011010|76.0|Repeated endoscopy at 6, 7 and 8 years old showed persistent chronic inflammation in the cecum, and pancolitis with diffuse inflammation, superficial ulceration, distortion of the crypt architecture and crypt abscess formation, in a distribution similar to that found in ulcerative colitis (Figure 1B).|['Chronic']|0.0|None|1.0|1|Further diagnostic work-up|15.0
<h5>Further diagnostic work-up</h5>. Liver biopsy showed hydropic degeneration of hepatocytes (Figure 1A).. There was no evidence of mitochondrial DNA depletion and plasma lactate was normal.. Repeated endoscopy at 6, 7 and 8 years old showed persistent chronic inflammation in the cecum, and pancolitis with diffuse inflammation, superficial ulceration, distortion of the crypt architecture and crypt abscess formation, in a distribution similar to that found in ulcerative colitis (Figure 1B).. There were no inflammatory changes in the esophagus, stomach and duodenum, nor were there any granuloma to suggest Crohn's disease.<br>Figure 1 Histology and blood leukocyte cytokine profile of patient with cytosolic isoleucyl-tRNA synthetase deficiency.<br>A: Liver histology showing hydropic change, but no classic apoptosis of the hepatocytes: B: Pancolitis, with diffuse increase in inflammatory cells, cryptitis and crypt abscess formation.. High power insert: A few apoptotic epithelial cells seen, but within normal limits, c/cytokine profile: C: Cytokine secretion from peripheral blood leukocytes of patient with isoleucyl-tRNA synthetase deficiency compared with healthy donor.|45.0|set()|HP:0002583|76.0|Repeated endoscopy at 6, 7 and 8 years old showed persistent chronic inflammation in the cecum, and pancolitis with diffuse inflammation, superficial ulceration, distortion of the crypt architecture and crypt abscess formation, in a distribution similar to that found in ulcerative colitis (Figure 1B).|['Colitis']|0.0|None|1.0|1|Further diagnostic work-up|30.0
<h5>Further diagnostic work-up</h5>. Liver biopsy showed hydropic degeneration of hepatocytes (Figure 1A).. There was no evidence of mitochondrial DNA depletion and plasma lactate was normal.. Repeated endoscopy at 6, 7 and 8 years old showed persistent chronic inflammation in the cecum, and pancolitis with diffuse inflammation, superficial ulceration, distortion of the crypt architecture and crypt abscess formation, in a distribution similar to that found in ulcerative colitis (Figure 1B).. There were no inflammatory changes in the esophagus, stomach and duodenum, nor were there any granuloma to suggest Crohn's disease.<br>Figure 1 Histology and blood leukocyte cytokine profile of patient with cytosolic isoleucyl-tRNA synthetase deficiency.<br>A: Liver histology showing hydropic change, but no classic apoptosis of the hepatocytes: B: Pancolitis, with diffuse increase in inflammatory cells, cryptitis and crypt abscess formation.. High power insert: A few apoptotic epithelial cells seen, but within normal limits, c/cytokine profile: C: Cytokine secretion from peripheral blood leukocytes of patient with isoleucyl-tRNA synthetase deficiency compared with healthy donor.|60.0|set()|HP:0100279|76.0|Repeated endoscopy at 6, 7 and 8 years old showed persistent chronic inflammation in the cecum, and pancolitis with diffuse inflammation, superficial ulceration, distortion of the crypt architecture and crypt abscess formation, in a distribution similar to that found in ulcerative colitis (Figure 1B).|['Ulcerative colitis']|0.0|None|1.0|1|Further diagnostic work-up|45.0
Release of Th1, Th2, Th17 and Treg pathway cytokines (IL-2, IL-4, IL-5, IL-9, IL-10, IL-13, IL-17A, IL-17F, TNFa and IFNb) that may be deranged in IBD were assayed by cytometric bead array (Becton Dickinson) after 5-d stimulation of purified memory CD4+ T cells with anti-CD2/CD3/CD28 monoclonal antibodies.. Secretion of some inflammatory (IL-2, IL-5, IL-13, IL-9) and immune regulatory (IL-10) cytokines by the patient memory CD4 T-cells was markedly elevated, while IL-17A, IL-17F, IFNb were lower and TNFa not significantly different compared to healthy donors (Figure 1C).<br>. <h5>FINAL DIAGNOSIS</h5>. Transient neonatal hepatitis and refractory very early-onset IBD due to cytosolic isoleucyl-tRNA synthetase.<br>. <h5>TREATMENT</h5>. His IBD was refractory to additional zinc supplementation, as well as immune modulation with mesalazine, corticosteroids, azathioprine, sirolimus and anti-TNF therapy (adalimumab).|26.0|set()|HP:0012115|92.0|Transient neonatal hepatitis and refractory very early-onset IBD due to cytosolic isoleucyl-tRNA synthetase.<br>|['Hepatitis']|0.0|None|1.0|1|FINAL DIAGNOSIS|13.0
Supportive evidence from additional cases and functional enzyme assays would be helpful in definitively confirming the role of the  gene in very early-onset IBD.. Assays are unfortunately not currently available.. This case report will hopefully lead to additional patients with very early-onset IBD due to variants in the  gene being reported by other clinicians.<br>. ARSs may be associated with T-cell dysfunction as seen in our patient, but the lack of improvement with most immunosuppressant drugs suggests that other inflammatory pathways are involved.. The high IL-10 level is in keeping with an ineffectual compensatory Treg response rather than a defect in this pathway.. There is some suggestion that sirolimus, which blocks mammalian target of rapamycin complex 1 may ameliorate the disease, but use of sirolimus in our patient made no difference to his clinical course.<br>|56.0|{'associated', 'may'}|HP:0005435|107.0|ARSs may be associated with T-cell dysfunction as seen in our patient, but the lack of improvement with most immunosuppressant drugs suggests that other inflammatory pathways are involved.|['Impaired T cell function']|0.0|None|0.0|1|DISCUSSION|28.0
There is some suggestion that sirolimus, which blocks mammalian target of rapamycin complex 1 may ameliorate the disease, but use of sirolimus in our patient made no difference to his clinical course.<br>. Maintaining optimal zinc levels may also help optimize aminoacyl-tRNA synthetase activity, but our patient had normal plasma zinc concentrations and zinc supplements did not help ameliorate his IBD.. It is possible that there are defects in cell turnover and resultant barrier dysfunction of gut mucosa leading to microbe-induced inflammation particularly in the colon.. Broad-spectrum antibiotics may help for severe exacerbations.<br>. <h5>CONCLUSION</h5>. This case report provides evidence for a novel monogenic cause of IBD that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br>|14.0|{'may'}|HP:0012828|112.0|Broad-spectrum antibiotics may help for severe exacerbations.<br>|['Severe']|0.0|None|0.0|1|DISCUSSION|7.0
It is possible that there are defects in cell turnover and resultant barrier dysfunction of gut mucosa leading to microbe-induced inflammation particularly in the colon.. Broad-spectrum antibiotics may help for severe exacerbations.<br>. <h5>CONCLUSION</h5>. This case report provides evidence for a novel monogenic cause of IBD that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br>. <h5>ACKNOWLEDGEMENTS</h5>. This research was made possible through access to data generated by the 100000 Genomes Project: http://www.genomicsengland.co.uk.|64.0|{'report', 'patients'}|HP:0012115|114.0|This case report provides evidence for a novel monogenic cause of IBD that should be considered, particularly in patients with very early-onset, poor response to treatment and a history of neonatal hepatitis.<br>|['Hepatitis']|0.0|None|1.0|1|CONCLUSION|32.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|4.0|{'patients'}|HP:0000518|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Cataract']|0.0|None|0.0|1|Table File 4|2.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|6.0|{'patients'}|HP:0000519|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Developmental cataract']|0.0|None|0.0|1|Table File 4|4.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|8.0|{'patients'}|HP:0001427|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Mitochondrial inheritance']|0.0|None|0.0|1|Table File 4|6.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|10.0|{'patients'}|HP:0100018|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Nuclear cataract']|0.0|None|0.0|1|Table File 4|8.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|12.0|{'patients'}|HP:0000824|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Growth hormone deficiency']|0.0|None|0.0|1|Table File 4|10.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|14.0|{'patients'}|HP:0001510|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Growth delay']|0.0|None|0.0|1|Table File 4|12.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|16.0|{'patients'}|HP:0004322|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Short stature']|0.0|None|0.0|1|Table File 4|14.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|18.0|{'patients'}|HP:0000365|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Hearing impairment']|0.0|None|0.0|1|Table File 4|16.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|20.0|{'patients'}|HP:0000407|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Sensorineural hearing impairment']|0.0|None|0.0|1|Table File 4|18.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|22.0|{'patients'}|HP:0008527|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Congenital sensorineural hearing impairment']|0.0|None|0.0|1|Table File 4|20.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|24.0|{'patients'}|HP:0006903|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Congenital peripheral neuropathy']|0.0|None|0.0|1|Table File 4|22.0
</span></td>. <td>. <span><b>Schwartzentruber J</b>,Buhas D,Majewski J,Sasarman F,Papillon-Cavanagh S,Thiffault I,Sheldon KM,Massicotte C,Patry L,Simon M,Zare AS,McKernan KJ:FORGE Canada Consortium, Michaud J, Boles RG, Deal CL, Desilets V, Shoubridge EA, Samuels ME.. Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>. <span>. <em>Hum Mutat</em>.|26.0|{'patients'}|HP:0009830|6.0|Mutation in the nuclear-encoded mitochondrial isoleucyl-tRNA synthetase IARS2 in patients with cataracts, growth hormone deficiency with short stature, partial sensorineural deafness, and peripheral neuropathy or with Leigh syndrome.</span>|['Peripheral neuropathy']|0.0|None|0.0|1|Table File 4|24.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|12.0|set()|HP:0001510|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Growth delay']|0.0|None|0.0|1|Table File 5|6.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|18.0|set()|HP:0001511|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Intrauterine growth retardation']|0.0|None|0.0|1|Table File 5|12.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|24.0|set()|HP:0003577|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Congenital onset']|0.0|None|0.0|1|Table File 5|18.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|30.0|set()|HP:0001249|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Intellectual disability']|0.0|None|0.0|1|Table File 5|24.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|36.0|set()|HP:0001252|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Muscular hypotonia']|0.0|None|0.0|1|Table File 5|30.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|42.0|set()|HP:0001290|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Generalized hypotonia']|0.0|None|0.0|1|Table File 5|36.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">3.. </span></td>. <td>. <span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>. <span>. <em>Am J Hum Genet</em>."|48.0|set()|HP:0001319|5.0|<span><b>Kopajtich R</b>,Murayama K,Janecke AR,Haack TB,Breuer M,Knisely AS,Harting I,Ohashi T,Okazaki Y,Watanabe D,Tokuzawa Y,Kotzaeridou U,Klker S,Sauer S,Carl M,Straub S,Entenmann A,Gizewski E,Feichtinger RG,Mayr JA,Lackner K,Strom TM,Meitinger T,Mller T,Ohtake A,Hoffmann GF,Prokisch H,Staufner C.Biallelic IARS Mutations Cause Growth Retardation with Prenatal Onset, Intellectual Disability, Muscular Hypotonia, and Infantile Hepatopathy.</span>|['Neonatal hypotonia']|0.0|None|0.0|1|Table File 5|42.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">4.. </span></td>. <td>. <span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>. <span>. <em>Clin Genet</em>."|12.0|set()|HP:0001510|5.0|<span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>|['Growth delay']|0.0|None|0.0|1|Table File 6|6.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">4.. </span></td>. <td>. <span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>. <span>. <em>Clin Genet</em>."|18.0|set()|HP:0001396|5.0|<span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>|['Cholestasis']|0.0|None|0.0|1|Table File 6|12.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">4.. </span></td>. <td>. <span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>. <span>. <em>Clin Genet</em>."|24.0|set()|HP:0001263|5.0|<span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>|['Global developmental delay']|0.0|None|0.0|1|Table File 6|18.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">4.. </span></td>. <td>. <span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>. <span>. <em>Clin Genet</em>."|30.0|set()|HP:0012825|5.0|<span><b>Orenstein N</b>,Weiss K,Oprescu SN,Shapira R,Kidron D,Vanagaite-Basel L,Antonellis A,Muenke M.Bi-allelic IARS mutations in a child with intra-uterine growth retardation, neonatal cholestasis, and mild developmental delay.</span>|['Mild']|0.0|None|0.0|1|Table File 6|24.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">6.. </span></td>. <td>. <span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>. <span>. <em>Clin Genet</em>."|12.0|{'association'}|HP:0001290|5.0|<span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>|['Generalized hypotonia']|0.0|None|0.0|1|Table File 8|6.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">6.. </span></td>. <td>. <span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>. <span>. <em>Clin Genet</em>."|18.0|{'association'}|HP:0001319|5.0|<span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>|['Neonatal hypotonia']|0.0|None|0.0|1|Table File 8|12.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">6.. </span></td>. <td>. <span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>. <span>. <em>Clin Genet</em>."|24.0|{'association'}|HP:0001249|5.0|<span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>|['Intellectual disability']|0.0|None|0.0|1|Table File 8|18.0
"<td style=""vertical-align:top:width:30px:""><span class=""article-ref-vol"">6.. </span></td>. <td>. <span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>. <span>. <em>Clin Genet</em>."|30.0|{'association'}|HP:0001510|5.0|<span><b>Smigiel R</b>,Biela M,Biernacka A,Stembalska A,Sasiadek M,Kosinska J,Rydzanicz M,Ploski R.New evidence for association of recessive IARS gene mutations with hepatopathy, hypotonia, intellectual disability and growth retardation.</span>|['Growth delay']|0.0|None|0.0|1|Table File 8|24.0
</span></td>. <td>. <span><b>Hong HJ</b>,Kim E,Jung MY,Kim S,Kim TS.. AIMP1 deficiency enhances airway hyperreactivity in mice via increased TH2 immune responses.</span>. <span>. <em>Clin Immunol</em>.|24.0|set()|HP:0002721|6.0|AIMP1 deficiency enhances airway hyperreactivity in mice via increased TH2 immune responses.</span>|['Immunodeficiency']|0.0|None|0.0|1|Table File 12|12.0
